SCHEMBL998466

SCHEMBL998466

O=C(Nc1ccccc1F)N1CCCc2[nH]c3ccccc3c2C1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 12/20 0.77
MAPT P10636 5/20 0.58
KMT2A Q03164 3/20 0.58
MEN1 O00255 2/20 0.58
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
MCL1 Q07820 1/20 0.58
KDM4E B2RXH2 2/20 0.56
ALDH1A1 P00352 2/20 0.56
HSD17B10 Q99714 2/20 0.56
ALOX15 P16050 1/20 0.56
TSHR P16473 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
MAPK1 P28482 1/20 0.55
CASP1 P29466 1/20 0.55
ATM Q13315 1/20 0.55
NPC1 O15118 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1000419 0.91 TRPV1 (0.88) TRPV1
SCHEMBL1078589 0.87 MAPT (0.64) TRPV1MAPTKMT2AMEN1CYP1A2
SCHEMBL998549 0.87 TRPV1 (1.00) TRPV1
SCHEMBL999153 0.84 MAPT (0.72) TRPV1MAPTKMT2AMEN1CYP1A2
SCHEMBL999355 0.78 TRPV1 (0.71) TRPV1MAPTKMT2AMEN1CYP1A2
SCHEMBL1000695 0.78 TRPV1 (0.61) TRPV1MAPTKMT2AMEN1CYP1A2
SCHEMBL997891 0.78 TRPV1 (0.88) TRPV1KMT2AMEN1
SCHEMBL998380 0.78 TRPV1 (0.65) TRPV1MAPTKMT2AMEN1KDM4E
SCHEMBL997622 0.76 TRPV1 (0.88) TRPV1MAPTKMT2AMEN1CYP1A2
SCHEMBL997850 0.76 TRPV1 (0.64) TRPV1MAPTKMT2AMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1637521-B1 NOVEL TRICYCLIC HETEROCYCLE COMPOUND ONO PHARMACEUTICAL CO (JP) 2013-06-19 EP disclosed
US-7872133-B2 Tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2011-01-18 US disclosed
US-20060154944-A1 Novel tricyclic heterocycle compound ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154944-A1 Novel tricyclic heterocycle compound CYP11B1, CYP11B2, HCCS TRPV1 2437/4885MAPT 4705/4885KMT2A 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.